July 19, 2018

Basilea reports receipt of milestone payment based on first Cresemba® approval in Latin America




Basel, Switzerland, July 19, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has received a CHF 2 million milestone payment from its partner Grupo Biotoscana S.L. ("GBT"), based on the first regulatory approval of the antifungal Cresemba® (isavuconazole) in Latin America.

Adesh Kaul, Chief Corporate Development Officer, said: "We are very pleased with the approval of Cresemba in Peru. This is the first approval of the brand in the important Latin America region and the first approval of Cresemba outside Europe and the U.S. We are looking forward to GBT making Cresemba available to patients in Peru and other Latin American countries following further regulatory approvals."

Basilea and GBT entered into a supply, distribution and licensing agreement for Cresemba and also for Basilea's antibiotic Zevtera in September 2016. The agreement covers 19 countries in Latin America and Basilea received an upfront payment of CHF 11 million. Basilea supplies GBT with Cresemba and Zevtera at a transfer price and is eligible to receive further milestone payments.

About Cresemba (isavuconazole)

Isavuconazole is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba. Basilea has entered into license and distribution agreements for isavuconazole covering the United States, Europe, China, Japan, Latin America, Canada, Russia, Turkey, Israel and the Asia-Pacific and Middle East and North Africa regions. In the 28 European Union member states, as well as in Iceland, Liechtenstein, Norway and Peru, isavuconazole is approved for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis for whom amphotericin B is inappropriate.1 It is also approved in the U.S. and Switzerland.2, 3 Isavuconazole has U.S. and European orphan drug designation for its approved indications.

About Basilea

Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.


This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
+41 61 606 1102

This press release can be downloaded from www.basilea.com.


1   European Public Assessment Report (EPAR) Cresemba: www.ema.europa.eu
[Accessed: July 18, 2018]

2   In the United States, Cresemba is approved to treat patients 18 years of age and older for invasive aspergillosis and invasive mucormycosis (Cresemba US prescribing information, accessed July 18, 2018).

3   In Switzerland, isavuconazole is approved for the treatment of adult patients with invasive aspergillosis and for the treatment of mucormycosis in adult patients who are resistant to or intolerant of amphotericin B and in adult patients with moderate to severe renal impairment (full indication in: Swissmedic-approved information for healthcare professionals as of August 2017).